Subscribe
shutterstock_121153783_sahara_prince
Sahara Prince / Shutterstock.com
5 July 2021Big PharmaAlex Baldwin

Five minutes with… Dmitry Karshtedt

Genus claims—or patent claims covering a family of related compounds—are commonplace in life sciences patent law. But following a rising trend of invalidity rulings, the future of the claim seems bleak.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
Five minutes with… Jacqueline Mulryne
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
Five minutes with… Penny Gilbert
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.


Editor's picks

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025

Editor's picks

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025
Americas
ADCs, TCR, and multimodal AI: Transformative trends in 2025
23 January 2025

More on this story

article
Five minutes with… Jacqueline Mulryne
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
Five minutes with… Penny Gilbert
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

More on this story

article
Five minutes with… Jacqueline Mulryne
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
Five minutes with… Penny Gilbert
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

More features

Amy Candido to head IP litigation team at Simpson Thacher
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
The rise of weight loss drugs: Regulators tighten up
Paul Hastings adds Latham tech transactions expert as co-chair
Why Abbott’s victory marks a turning point for UPC preliminary injunctions
Natera loses $96m jury win as judge invalidates DNA test patents
Fed Circ’s Wuhan v ITC ruling opens ITC door to small corps
Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules